Home > Maligne hematologie > Myeloïde ziekten > Myeloproliferatieve aandoeningen > Essentiele trombocytose (ET) > MK3543-006 ET

MK3543-006 ET

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants with Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea.

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 21-3-2025, 10:46